Effects of Disease-Worsening Following Withdrawal of Etanercept or Methotrexate on Patient-Reported Outcomes in Patients With Rheumatoid Arthritis: Results From the SEAM-RA Trial.

J Clin Rheumatol · 2023 · PMC9803379 · PMID 36459119

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

nominally significantp < 0.05actually significant

Patients receiving etanercept monotherapy had less deterioration of PtGA and PtJP scores versus those assigned to methotrexate monotherapy, with a nominally significant treatment difference observed at almost all time points for PtGA and PtJP at weeks 12 and 36 ( p < 0.05; Fig. 1 ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.